1. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
by Marie-Anne Hospital, Thomas Prebet, Sarah Bertoli, Xavier Thomas, Emmanuelle Tavernier, Thorsten Braun, Cécile Pautas, Aurore Perrot, Bruno Lioure, Philippe Rousselot, Jérôme Tamburini, Thomas Cluzeau, Johanna Konopacki, Edouard Randriamalala, Céline Berthon, Marie-Pierre Gourin, Christian Recher, Jean-Yves Cahn, Norbert Ifrah, Hervé Dombret, and Nicolas Boissel
Blood
Volume 124(8):
August 21, 2014
©2014 by American Society of Hematology

2. Patient flowchart.
Patient flowchart. Induction and consolidation therapy according to GO administration in salvage therapy.
Marie-Anne Hospital et al. Blood 2014;124:
©2014 by American Society of Hematology

3. Outcome of CBF-AML patients after first relapse (N = 145).
Outcome of CBF-AML patients after first relapse (N = 145). DFS and OS according to (A) CBFA vs CBFB status, (B) CR1 duration (<1 vs ≥1 year), and (C) administration of GO in salvage therapy.
Marie-Anne Hospital et al. Blood 2014;124:
©2014 by American Society of Hematology

4. Impact of autoSCT, alloSTC, and GO administration in CBF-AML patients after relapse.
Impact of autoSCT, alloSTC, and GO administration in CBF-AML patients after relapse. Plots by Simon and Makuch for DFS and OS in nonallogeneic transplanted patients (N = 67) according to autoSCT. (A) For the whole cohort of patients according to allogeneic transplantation and (B) in allogeneic transplanted patients (N = 77) according to GO administration before transplant (C).
Marie-Anne Hospital et al. Blood 2014;124:
©2014 by American Society of Hematology